JP2002531505A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531505A5
JP2002531505A5 JP2000586335A JP2000586335A JP2002531505A5 JP 2002531505 A5 JP2002531505 A5 JP 2002531505A5 JP 2000586335 A JP2000586335 A JP 2000586335A JP 2000586335 A JP2000586335 A JP 2000586335A JP 2002531505 A5 JP2002531505 A5 JP 2002531505A5
Authority
JP
Japan
Prior art keywords
dnj
composition
nonyl
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000586335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531505A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/027918 external-priority patent/WO2000033843A1/en
Publication of JP2002531505A publication Critical patent/JP2002531505A/ja
Publication of JP2002531505A5 publication Critical patent/JP2002531505A5/ja
Pending legal-status Critical Current

Links

JP2000586335A 1998-12-10 1999-12-08 糖脂質蓄積症を治療する薬物製造のためのデオキシノジリマイシンの長鎖n−アルキル誘導体の使用 Pending JP2002531505A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11168398P 1998-12-10 1998-12-10
US60/111,683 1998-12-10
PCT/US1999/027918 WO2000033843A1 (en) 1998-12-10 1999-12-08 Use of long-chain n-alkyl derivatives of deoxynojirimycin for the manufacture of a medicament for the treatment of glycolipid storage diseases

Publications (2)

Publication Number Publication Date
JP2002531505A JP2002531505A (ja) 2002-09-24
JP2002531505A5 true JP2002531505A5 (https=) 2007-01-11

Family

ID=22339901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586335A Pending JP2002531505A (ja) 1998-12-10 1999-12-08 糖脂質蓄積症を治療する薬物製造のためのデオキシノジリマイシンの長鎖n−アルキル誘導体の使用

Country Status (11)

Country Link
US (1) US6610703B1 (https=)
EP (1) EP1137416B1 (https=)
JP (1) JP2002531505A (https=)
AT (1) ATE226821T1 (https=)
AU (1) AU2347500A (https=)
CA (1) CA2352544C (https=)
DE (1) DE69903750T2 (https=)
DK (1) DK1137416T3 (https=)
ES (1) ES2190674T3 (https=)
PT (1) PT1137416E (https=)
WO (1) WO2000033843A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
GB9909064D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7994198B2 (en) 2002-07-17 2011-08-09 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
AU2003246942B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
EP1811991B1 (en) * 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
SI2032134T1 (sl) 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
EP2594564B1 (en) 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CN101888840A (zh) 2007-10-05 2010-11-17 简詹姆公司 使用脑酰胺衍生物治疗多囊性肾疾病的方法
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
CN102369023A (zh) 2008-12-16 2012-03-07 建新公司 寡糖-蛋白缀合物
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
EP2400843B1 (en) * 2009-02-24 2015-11-11 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
EP2411526A4 (en) * 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc MODULATORS OF GANGLIOSID BIOSYNTHESIS
ES2524361T3 (es) * 2009-06-12 2014-12-05 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por bunyavirus y togavirus
CA2772813A1 (en) * 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Iminosugars and methods of treating filoviral diseases
JP5653438B2 (ja) * 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション オルトミクソウイルス感染の治療方法
CA2772807A1 (en) * 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Methods of treating poxviral infections
CA3140959A1 (en) 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2014017915A2 (en) 2012-07-27 2014-01-30 Universiteit Utrecht Holding B.V. Urea and guanidinium derivatives of iminosugars
CN106102464A (zh) * 2013-05-02 2016-11-09 牛津大学之校长及学者 采用亚氨基糖的糖脂抑制
WO2016126572A2 (en) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
EP4048397B1 (en) 2019-10-23 2023-08-16 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors for therapeutic applications
EP4142878B1 (en) 2020-04-28 2024-06-26 The Regents of The University of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
KR102826412B1 (ko) * 2022-11-01 2025-06-26 차의과학대학교 산학협력단 N-노닐데옥시노지리마이신을 포함하는 피부 가려움증의 억제, 경감, 개선, 또는 치료를 위한 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3507019A1 (de) * 1985-02-28 1986-08-28 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5798366A (en) 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
ATE322900T1 (de) 1996-07-15 2006-04-15 Macrozyme Dnm B V Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
CA2252238A1 (en) 1997-10-31 1999-04-30 Sun Microsystems, Inc. Method and apparatus for sharing a time quantum

Similar Documents

Publication Publication Date Title
JP2002531505A5 (https=)
JP4925074B2 (ja) ミルタザピンと1種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
NZ514574A (en) Novel method of treatment
CA2382098A1 (en) Sustained-release, oral pharmaceutical forms of administration
AU6050600A (en) Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidaseenzyme for the manufacture of medicament for the treatment of glycolipid storag e diseases
AU1708202A (en) Organic compounds
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
AU2347500A (en) Use of long-chain n-alkyl derivatives of deoxynojirimycin for the manufacture ofa medicament for the treatment of glycolipid storage diseases
HU9403693D0 (en) Methods of treating menstrual symptoms and compositions therefore
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
JP2002519425A5 (https=)
EP0897721A3 (en) Benzo(b)thiophene derivatives for inhibiting detrimental side-effects due to GnRH or GnRH agonist administration
RU94045278A (ru) Применение 2-фенил-3-ароилбензтиофенов для ингибирования вазомоторных симптомов и сопутствующих психологических нарушений, ассоциированных с постклимактерическим синдромом
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
RU2000122435A (ru) Производные индола и фармацевтические композиции, включающие их
CA2270955A1 (en) Pharmaceutical composition containing morphinan derivative for treating drug dependence
BR9503775A (pt) Compostos e composição farmacêutica útil como um agente analgésico antiinflamatório diurético ou neuroprotetor
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
SI1177167T1 (en) High purity (1r, 2s, 4r)-(-)-2-((2'-(n,n-dimethylamino)-ethoxy))-2-(phenyl)-1,7,7-tri-(methyl)-bicyclo(2.2.1)heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them.
JP2002522462A5 (https=)
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat